What are the aims of this leaflet?
This leaflet provides you with information about stage 1B melanoma. The following information tells you what a stage 1B melanoma is, what will be the investigations/treatments and where to find out more information. It has been prepared in response to some of the questions people with melanoma often ask.
What is melanoma?
Melanoma is a type of skin cancer, which arises from the pigment cells (melanocytes) in the skin. One of the most important causes of melanoma is exposure to too much ultraviolet light in sunlight. The use of artificial sources of ultraviolet light, such as sunbeds, also increases the risk of getting a melanoma.
Melanoma is considered to be the most serious type of skin cancer because it is more likely to spread (metastasise) from the skin to other parts of the body than other types of skin cancer. If melanoma has spread to other parts of the body, those deposits are known as secondary melanoma (secondaries/metastases). Although a diagnosis of melanoma can be serious, most melanomas are diagnosed at an early stage and so do not cause any further problem. If lesions are not removed at the early stages then there is a higher risk of the melanoma spreading, which can reduce life expectancy.
How is Melanoma diagnosed?
The clinical diagnosis of melanoma is usually made by a specialist (normally a dermatologist or plastic surgeon) by looking at the skin. The initial treatment for a suspected melanoma is to cut out (excise) all of the melanoma cells. Usually this is a minor operation done under a local anaesthetic (via an injection to numb the skin). When the lesion is first removed, although your specialist may feel that it is likely to be a melanoma, the diagnosis needs to be confirmed by examining the tissue removed under a microscope, so the excision is usually done with narrow margins (a thin rim of normal skin around the suspected melanoma). The specimen that is cut out from the skin is sent to a laboratory, so that a pathologist can examine it under the microscope and then confirm the diagnosis of melanoma.
If you have been given this leaflet by your doctor, you will have probably had this initial minor operation and had your diagnosis of melanoma confirmed by the pathologist
What is stage 1B melanoma?
Doctors use a staging system for melanoma to indicate both the likely outcome and the best treatment. The AJCC (American Joint Committee on Cancer) system is currently used in the UK to stage melanoma from 1 to 4. Stage 1 is the earliest melanoma and stage 4 is the most advanced.
The staging system takes into account the thickness of melanoma and if there has been any spread of melanoma from the skin to other parts of the body. Stage 1 and 2 melanomas are present in the skin only and have not spread elsewhere in the body. Stage 3 have spread towards or have reached the draining lymph glands (nodes) and Stage 4 melanomas are those that have spread beyond the closest draining lymph glands to other parts of the body.
The pathologist will look under the microscope to assess certain features of the melanoma. The most important of all of these is the thickness of the melanoma (called Breslow thickness), which measures how deep the melanoma cells have grown down into the layers of skin. The pathologist uses this measure and some other additional features such as ulceration of the melanoma (seen down the microscope) to create a histology report on your melanoma and we can then work out the AJCC stage.
Stage I melanomas can be split into stage 1A and stage 1B. A stage 1B melanoma can be categorised as either
- A melanoma with a thickness between 0.8mm to 2 mm with no ulceration.
Or
- A melanoma with a thickness less than 0.8mm with ulceration.
You can discuss your staging in more detail with the medical team looking after you, if you would like to know more.
What happens next?
A multidisciplinary team (MDT) of experts will meet to discuss the best treatment option(s) for you. The MDT is made up of dermatologists, surgeons, pathologists, oncologists and specialist nurses. A member of the MDT will explain your treatment options to you and you may also meet a melanoma/skin cancer clinical nurse specialist (CNS) who would be a point of contact for you and advise you accordingly.
How is stage 1B melanoma treated?
Removing the melanoma from the skin by surgery offers the best chance of a complete cure, and this treatment alone is usually successful in stage 1 melanoma. Most patients do NOT need either radiotherapy or chemotherapy.
After the melanoma is initially removed for histological diagnosis you will usually be offered a second surgical procedure to remove more skin from around and beneath the melanoma scar. This second procedure typically removes a further 1cm margin of skin around the first scar site. It is called a Wide Local Excision (WLE) and is usually also carried out under local anaesthetic. The purpose of this further surgery is to try and make sure that no cancer cells are left behind in the nearby skin and to minimise the risk of the melanoma recurring.
What scar(s) can I expect following a wide local excision?
The type of scar(s) will depend on location and the type of surgical technique required. The WLE might result in a scar similar in shape but bigger in size than the one that was left by cutting out the original melanoma. Some scars can be more complex in shape because a “flap” or skin graft was required. Further information on flaps and grafts can be found via the website links given at the end of the leaflet. Occasionally lumpy scars called “keloids” may result and this is more common on upper arms and chest over breast bone. Scars can feel hard and itchy at first but usually will fade and soften with time. Stopping smoking, after any surgery, can improve wound healing.
What is a sentinel lymph node biopsy?
Following your examination with your doctor, some patients with stage IB melanoma may be offered a further staging test called a sentinel lymph node biopsy to detect whether there has been any spread of the melanoma. If melanoma spreads from the skin, it tends to spread first to the nearest lymph glands.
A sentinel node biopsy (SNB) is currently an optional test to see whether there has been spread of a small number of melanoma cells to these nearest lymph glands early before a swelling can be detected by examination.
An SNB is carried out at the same time as the WLE and the procedure will be done under general anaesthetic (while you are asleep). The test involves identifying the nearest gland(s) (which is the sentinel gland) and then removing the gland(s) so that they can be sent to the pathology laboratory for examination under the microscope (see diagram below). It is a very sensitive test as this can detect microscopic melanoma cells that cannot be felt or even seen on a scan.
Before your operation to remove the sentinel lymph glands you will have a lymphoscintogram, which helps your doctors map out your nearest lymph glands. This involves injecting a small amount of radioactive dye into the scar where your melanoma was, followed by a scan which follows the route of the dye into the lymph glands. The position of these glands can then be marked on your skin to help the surgeon accurately identify the correct gland for removal. During the operation, the surgeon will then also inject a blue dye into your scar which also travels into the lymph glands. It is the combination of the radioactive dye and the blue dye which helps to accurately identify the sentinel lymph gland. The surgeon will remove that gland (sometimes nearest 2-3 glands) at the same time as carrying out the WLE. The operation usually takes less than an hour. The WLE skin samples and SNB glands are all sent to the pathology laboratory for further analysis. You are usually able to go home the same day of the operation.
The results usually take 4 weeks to come back. If melanoma cells are detected in the gland (a positive sentinel node biopsy) then this changes your stage of melanoma to stage 3. Historically following a positive sentinel node biopsy, patients would be offered a further operation to remove all the lymph glands in that site (called a completion lymphadenectomy/complete lymph gland/node clearance). However new evidence suggests that this further procedure does not improve survival from melanoma. This is therefore no longer routinely recommended.
If there is no melanoma in the gland (a negative sentinel node biopsy) you will remain stage IB. A negative result does not mean the melanoma will definitely not come back but the chances of this are much lower. The sentinel lymph node biopsy remains optional because it is not classed as a treatment, but it is recommended as a staging process which gives you more information about your melanoma. There are advantages and disadvantages to the procedure which can be found in the sentinel lymph node biopsy information link listed below. Complications from a sentinel lymph node biopsy include infection, bleeding, numbness, scarring, seroma (a swelling of fluid that can take a while to settle), small chance of lymphoedema (permanent swelling of the limb) and an allergic reaction to the blue dye can occur in 1 in 1000.
Please discuss this information further with your medical team so that you can make the right decision for you.
What is the risk of stage 1B melanoma recurring?
A diagnosis of stage 1B melanoma means it has been caught early and most patients don’t have further recurrence of their melanoma once treated. There are statistics available on the likelihood of melanoma recurrence for each stage of melanoma. If you want to know more precisely the chances of your melanoma recurring, talk to your dermatologist and/or your CNS. Dealing with details of this and treatment can however be emotionally trying.It may be difficult to take everything in that the doctor tells you during the consultation. This leaflet is designed to add to the information that the doctor gives you, but your own doctor and their team remain the best source of information for you.
After treatment, why am I followed up?
Patients are routinely followed up in the out-patient clinics after the completion of the WLE for three reasons:
- To check that the melanoma has not come back or spread.
- To detect new melanomas or other skin cancers.
- To provide support, information and education.
How often and for how long will I be followed up?
The follow-up plan is accordingly to National Guidelines for melanoma. You will most likely be followed up for 5 years, seeing your doctor or cancer nurse specialist (CNS) every 3 months, for the first 3 years and then every 6 months for the last 2 years. It is common for your follow up to be shared between different doctors, and/or a CNS, involved in your care.
How will a recurrence of the melanoma or a new melanoma be detected?
Your doctor will want to examine the area of your melanoma scar and also check your lymph nodes (glands). They will also ask to examine your entire skin to make sure there are no signs of any new melanomas. Photographs might be taken to help compare the way your moles look now with how they looked before and will be kept in your notes if you agree. If a new or recurrent melanoma is suspected then, as before, it will most likely be removed surgically.
What makes somebody more at risk of developing a new melanoma?
One of the biggest risk factors is a strong family history of melanoma. (if there are 3 or more of your family members affected by melanoma then your medical team would discuss genetic counselling with you). The following are also risk factors for developing melanoma:
- A large number of moles, and moles, which are large and irregular in colour and shape (‘atypical” moles).
- Having fair skin that burns easily in the sun, freckles and/or red hair.
- A history of severe sunburn, especially sunburn that caused blisters, occurring in childhood.
- A “weaker” family history of melanoma, i.e. only 1 or 2 other family members affected.
- Having a very large dark birthmark (a giant congenital mole)
- Having already had a melanoma.
- A weakened immune system (for example, because of treatment with immunosuppressive drugs)
Self care (What can I do?)
Normally, your CNS will discuss the following with you after treatment:
You can examine your skin
Most patients do not develop further melanomas; however, some do and they may also develop other forms of skin cancer. The best way to detect skin cancer is to check all your skin every month (please see Patient Information Leaflet on early detection). Essentially, you are looking for changes in the size, shape or colour of any moles, a new mole, or a mole that looks different to the others. There are patient information web-packages, which outline how to look after your moles (please see the web links at the end of this leaflet).
Reduce the risk of further melanomas.
The best way you can reduce risk is to not let your skin burn in the sun. You do not have to hide during sunny days, but you do need to be careful to avoid turning pink and this applies also to any children you have as they are likely to have a similar skin type to you. Information on the best methods of sun protection can be found on the website links provided at the end of this leaflet (see Patient Information Leaflet on prevention).
Top sun safety tips:
- Protect your skin with clothing, and don’t forget to wear a hat that protects your face, neck and ears, and a pair of UV protective sunglasses.
- Spend time in the shade between 11am and 3pm when it’s sunny. Step out of the sun before your skin has a chance to redden or burn.
- When choosing a sunscreen look for a high protection SPF (SPF 30 or more) to protect against UVB, and the UVA circle logo and/or 4 or 5 UVA stars to protect against UVA. Apply plenty of sunscreen 15 to 30 minutes before going out in the sun, and reapply every two hours and straight after swimming and towel-drying.
- Keep babies and young children out of direct sunlight.
- The British Association of Dermatologists recommends that you tell your doctor about any changes to a mole or patch of skin. If your GP is concerned about your skin, make sure you see a Consultant Dermatologist – an expert in diagnosing skin cancer. Your doctor can refer you for free through the NHS.
- Sunscreens should not be used as an alternative to clothing and shade, rather they offer additional protection. Sunscreens do not provide 100% protection.
Vitamin D advice
The evidence relating to the health effects of Vitamin D blood levels, sunlight exposure and Vitamin D intake remains inconclusive. Avoiding all sunlight exposure if you suffer from light sensitivity, or to reduce the risk of melanoma and other skin cancers, may be associated with Vitamin D deficiency. Patients diagnosed with melanoma are advised to have their Vitamin D level checked by their hospital team. If levels are low they are advised to consider taking vitamin D3, 10-20 micrograms (400-800IU) per day, and increasing their intake of foods high in Vitamin D such as oily fish, eggs, meat, fortified margarines and cereals. Vitamin D3 supplements are widely available from supermarkets and chemists. Specific advice will be given by your doctor depending on your level of Vitamin D. |
Having had a melanoma may impact on future applications for life or health insurance, particularly for the first five years after diagnosis. Equally you may be able to make a claim against any critical illness insurance, you may have taken out prior to the diagnosis of melanoma. If you have particular concerns about this, you should seek financial advice.
Where can I get more advice, support & information about melanoma?
When you have been diagnosed with melanoma you might experience a range of emotions including worry, confusion or even feeling unable to cope. It will probably help if you discuss and share your thoughts and feelings with someone close. This might be a family member or friend. It could also be your doctor, CNS or another member of the team looking after you.
When you are diagnosed with melanoma, you will be given a lot of information. All this information at once can be hard to take in. If you are not clear about anything during your treatment, please don’t be afraid to ask.
Web links to detailed leaflets:
British Association of Dermatologists
- Information on early detection and prevention of melanoma
http://www.bad.org.uk/for-the-public/skin-cancer/melanoma-leaflets - Information on sun-safety
http://www.bad.org.uk/for-the-public/sun-awareness-campagin
http://www.bad.org.uk/for-the-public/skin-cancer/sunscreen-fact-sheet - Information on Vitamin D
http://www.bad.org.uk/vitaminD
Cancer Research UK (CRUK)
- cancerhelp.cancerresearchuk.org/type/melanoma/
- Information on sun-safety
https://www.cancerresearchuk.org/about-cancer/causes-of-cancer/sun-uv-and-cancer
GenoMEL: The Melanoma Genetics Consortium
- Information on looking after your moles and vitamin D
http://genomel.org/info-for-patients/%EF%BF%BCsun-protection-and-vitamin-d-after-a-diagnosis/
Melanoma Focus
- Patient Decision Aid
https://pda.melanomafocus.com/
- Sentinel Node Consensus
https://melanomafocus.com/wp-content/uploads/2019/01/SNB-Consensus-Final-1.pdf
Macmillan Cancer Support
- www.macmillan.org.uk/Cancerinformation/Cancertypes/Melanoma/Melanoma.aspx
- Information on flaps/grafts
www.macmillan.org.uk/Cancerinformation/Cancertypes/Melanoma/Treating%20melanoma/Surgery/Surgery.aspx - Financial support
http://www.macmillan.org.uk/HowWeCanHelp/FinancialSupport/Financialguidance/Financialguidance.aspx
National Cancer Action Team (NCAT)/ NHS Choices
- Information on Vitamin D
www.nhs.uk/Conditions/vitamins-minerals/Pages/Vitamin-D.aspx
Jargon Buster: https://www.skinhealthinfo.org.uk/support-resources/jargon-buster/
Please note that the BAD provides web links to additional resources to help people access a range of information about their treatment or skin condition. The views expressed in these external resources may not be shared by the BAD or its members. The BAD has no control of and does not endorse the content of external links.
This leaflet aims to provide accurate information about the subject and is a consensus of the views held by representatives of the British Association of Dermatologists: individual patient circumstances may differ, which might alter both the advice and course of therapy given to you by your doctor.
This leaflet has been assessed for readability by the British Association of Dermatologists’ Patient Information Lay Review Panel
BRITISH ASSOCIATION OF DERMATOLOGISTS PATIENT INFORMATION LEAFLET
PRODUCED FEBRUARY 2019
NEXT REVIEW DATE FEBRUARY 2022